



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5

In re application of:

RENNER *et al.*

Appl. No. 09/449,631

Filed: November 30, 1999

For: **Ordered Molecular Presentation  
of Antigens, Method of  
Preparation and Use**

Art Unit: 1646

Examiner: To be assigned

Atty. Docket: 1700.0030002/JAG/SGW

### Information Disclosure Statement

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Applicants note that Document No. AI2, cited on the accompanying Form PTO-1449, is a non-English language PCT application. In accordance with M.P.E.P. § 609 A, Applicants submit herewith Document No. AA2, which issued from a U.S. national phase application based on Document No. AI2. Thus, Applicants believe that Document No. AA2 is an English language equivalent of Document No. AI2.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present patent application


does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that was cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date but before the mailing date of a first Office Action on the merits. No statement or fee is required. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed. A duplication copy of this pleading is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Stephen G. Whiteside  
Attorney for Applicants  
Registration No. 42,224

Date: 4/14/00

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600